CSIMarket Company Name, Ticker, Suppliers, else..
 

Syros Pharmaceuticals Inc   (NASDAQ: SYRS)

Syros Pharmaceuticals Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

SYRS Sales vs. its Competitors Q3 2024


Comparing the current results to its competitors, Syros Pharmaceuticals Inc reported Revenue decrease in the 3 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 7.34 %, recorded in the same quarter.

• List of SYRS Competitors





Revenue Growth Comparisons




Net Income Comparison

Syros Pharmaceuticals Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 556.07 %

<<  SYRS Stock Performance Comparisons


Syros Pharmaceuticals Inc 's Comment on Competition and Industry Peers


The company operates within the pharmaceutical and biotechnology industries, which are marked by rapid technological advancements and intense competition. It competes with major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. The company focuses on developing cancer therapies and faces competition from divisions of large pharmaceutical companies and biotechnology firms of various sizes. Current cancer treatments include surgery, radiation, chemotherapy, hormone therapy, and targeted drug therapy, often used in combination. Competitors may possess greater financial resources and expertise in research, development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry mergers and acquisitions have led to resource concentration among fewer competitors.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Syros Pharmaceuticals Inc




Lantern Pharma Inc
Share Performance



-38.75%
This Year
Lantern Pharma Inc
Profile

Lantern Pharma Inc's business model focuses on leveraging artificial intelligence and machine learning to identify and repurpose existing drugs for the treatment of various diseases.

More about Lantern Pharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 23.666 mill. $ - mill. $ -18.653 mill.


Nextcure Inc
Share Performance



+148.25%
This Quarter
Nextcure Inc
Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 40.971 mill. $ - mill. $ -54.664 mill.


Oncternal Therapeutics Inc
Share Performance



-82.95%
This Quarter
Oncternal Therapeutics Inc
Profile

Oncternal Therapeutics Inc's business model focuses on developing and commercializing novel therapies for the treatment of cancer.

More about Oncternal Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2.220 mill. $ 2.161 mill. $ -34.575 mill.


Oramed Pharmaceuticals Inc
Share Performance



-0.40%
Over The Past 5 Days
Oramed Pharmaceuticals Inc
Profile

Oramed Pharmaceuticals Inc. is a biopharmaceutical company with a business model focused on developing innovative oral drug delivery solutions.

More about Oramed Pharmaceuticals Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 212.931 mill. $ - mill. $ 174.864 mill.


Panbela Therapeutics Inc
Share Performance



-99.94%
One Year
Panbela Therapeutics Inc
Profile

Panbela Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative and effective treatments for pancreatic cancer. They aim to leverage their expertise in drug development and strategic partnerships to bring novel therapies to the market and address the unmet medical needs of patients with this devastating disease.

More about Panbela Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.000 mill. $ - mill. $ -27.917 mill.

80 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Syros Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Syros Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.